Why “nanobots in the bloodstream by the 2030s” underestimates the commercial, clinical and regulatory grind.

BVLOS is just the start—who owns orchestration and uptime?.

What fixed-wing electrics must clear for regional routes to pencil out.

Why component vendors may capture value before reactors do.